MedTrace Logo

Fresh Autologous Whole Blood Transfusion After Cardiopulmonary Bypass

NCT03204357 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2024-11-21

No results posted yet for this study

Summary

Autologous blood transfused at the end of cardiopulmonary bypass will reduce total blood loss 24 hours after surgery and improve mitochondrial oxygen delivery measured by plasma succinate levels.

The study design is a prospective randomized interventional trial of transfusion of fresh autologous whole blood versus standard of care expectant management of bleeding during elective cardiac surgery.

Conditions

  • Cardiac Disease
  • Bleeding Postoperative

Interventions

OTHER

Fresh Autologous whole Blood

Subjects randomized this arm will receive fresh autologous whole blood

OTHER

Standard of Care Expectant management of bleeding

the control group that will receive the standard of care expectant management of bleeding and transfusion of allogenic banked blood products

Sponsors & Collaborators

  • University of Colorado, Denver

    lead OTHER

Principal Investigators

  • Nathan Clendenen, M.D. · University of Colorado - School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-24
Primary Completion
2025-08-31
Completion
2026-09-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03204357 on ClinicalTrials.gov